Melanoma & Skin Cancer | Specialty

The melanoma & skin cancer condition center is a comprehensive resource for clinical news and expert insights on melanoma & skin cancer. Read more at OncLive.

PLN-101095 Plus Pembrolizumab Displays Activity in ICI-Refractory Advanced Solid Tumors

December 4th 2025

PLN-101095 in combination with pembrolizumab led to responses in patients with ICI-refractory advanced solid tumors.

Updated Cosibelimab Label Reflects Long-Term Data in Advanced CSCC

December 2nd 2025

The prescribing information for cosibelimab in advanced cutaneous squamous cell carcinoma was updated to include long-term data from the CK-301-101 trial.

sNDA for Aminolevulinic Acid Gel Plus PDT in sBCC Is Submitted to the FDA

December 2nd 2025

Biofrontera has submitted a sNDA to the FDA seeking the approval of aminolevulinic acid gel plus PDT in sBCC.

Adjuvant Cemiplimab Cleared in EU for CSCC With High Recurrence Risk After Surgery and Radiation

November 19th 2025

Cemiplimab wins EU approval after C-POST shows DFS gains for high-risk CSCC, marking the first effective adjuvant immunotherapy option.

Five Under 5: Top Oncology Videos for the Week of 11/9

November 16th 2025

The top 5 OncLive TV videos of the week cover insights in breast cancer, uveal melanoma, prostate cancer, and multiple myeloma.

AMT-253 Demonstrates Early Efficacy and Manageable Safety in Melanoma

November 15th 2025

AMT-253 delivered durable responses in patients with melanoma with manageable toxicity, supporting continued development.

Darovasertib Plus Crizotinib Could Represent Systemic Therapy Intended for Broader Metastatic Uveal Melanoma Population

November 7th 2025

Marlana Orloff, MD, discusses data for the combination of darovasertib and crizotinib in metastatic uveal melanoma.

Immune-Modulatory and mRNA-Based Cancer Vaccines Could Boost Benefit With ICIs Across Solid Tumors

November 5th 2025

Three experts spotlight key trials from the 2025 ESMO Congress investigating novel cancer vaccines across solid tumors.

OncLive’s October EMA Regulatory Recap: Key EU Approvals in Oncology

November 3rd 2025

Here is your snapshot of all oncologic therapeutic options that were approved by the EMA in October 2025.

The OncFive: Top Oncology Articles for the Week of 10/26

November 1st 2025

Belzutifan-based combinations meet end points in RCC, imaging agent under review for SSTR-positive neuroendocrine tumors, and more.

Cemiplimab Receives Reimbursement in Seven Provinces for NSCLC, Basal Cell Carcinoma

October 31st 2025

Seven provinces have agreed to reimburse cemiplimab for the treatment of patients with advanced non–small cell lung cancer and basal cell carcinoma.

OncLive’s October Roundup of Key FDA Approvals in Oncology: 4 Decisions to Know

October 31st 2025

Here is your guide to all therapeutic options that were approved by the FDA in October 2025 spanning tumor types.

Frontline Darovasertib Plus Crizotinib Shows Clinical Efficacy in Metastatic Uveal Melanoma

October 28th 2025

Darovasertib plus crizotinib improved OS to 21.1 months and boosted response rates in first-line metastatic uveal melanoma vs historical approaches.

EVX-01 Plus Pembrolizumab Drives Durable Disease Control, T-Cell Responses in Advanced Melanoma

October 27th 2025

EVX-01 plus pembrolizumab generated an overall response rate of 75% and durable T-cell responses in advanced melanoma.

The OncFive: Top Oncology Articles for the Week of 10/19

October 25th 2025

The FDA has cleared BVd for multiple myeloma and revumenib for NPM1-mutant AML, and granted priority review to perioperative enfortumab vedotin in MIBC.

FDA Approval Insights: Adjuvant Cemiplimab for High-Risk CSCC: With Vishal A. Patel, MD, FAAD, FACMS

October 23rd 2025

Dr Patel discusses the clinical relevance of the FDA approval of adjuvant cemiplimab for the management of high-risk cutaneous squamous cell carcinoma.

Adjuvant Cemiplimab Approval Redefines Management of High-Risk CSCC

October 23rd 2025

Adjuvant cemiplimab significantly cut recurrence risk and improved disease-free survival in high-risk CSCC, establishing a new standard of care.

Dr Hassel on the Rationale for Combining IO102-IO103 with Pembrolizumab in Treatment-Naive Advanced Melanoma

October 22nd 2025

Jessica C. Hassel, MD, discusses rationale for combining IO102-IO103 with pembrolizumab in patients with treatment-naive advanced melanoma.

FDA Grants Fast Track Status to NBM-BMX for Metastatic Uveal Melanoma

October 21st 2025

The FDA granted fast track to NBM-BMX, a HDAC8 inhibitor, for metastatic uveal melanoma.

NADINA Trial Favors Neoadjuvant Nivolumab/Ipilimumab in Resectable Stage III Melanoma

October 20th 2025

Neoadjuvant nivolumab plus ipilimumab proved superior to adjuvant nivolumab alone with longer follow-up data from the NADINA trial in stage III melanoma.